Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.

Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML.

Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613-0. doi: 10.1016/j.ygyno.2019.10.026. [Epub ahead of print]

PMID:
31759774
2.

The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.

Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, Hampel H, Kauff ND, Kitchener HC, Kitson SJ, Manchanda R, McMahon RFT, Monahan KJ, Menon U, Møller P, Möslein G, Rosenthal A, Sasieni P, Seif MW, Singh N, Skarrott P, Snowsill TM, Steele R, Tischkowitz M; Manchester International Consensus Group, Evans DG.

Genet Med. 2019 Oct;21(10):2390-2400. doi: 10.1038/s41436-019-0489-y. Epub 2019 Mar 28.

3.

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16.

4.

Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.

Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, Kelly Marcom P, Shelley Hwang E, Kauff ND, Greenup RA.

Ann Surg Oncol. 2017 Oct;24(11):3116-3123. doi: 10.1245/s10434-017-5995-z. Epub 2017 Jul 11.

5.

High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.

Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.

Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.

6.

Is There a Role for Ovarian Cancer Screening in High-Risk Women?

Berchuck A, Havrilesky LJ, Kauff ND.

J Clin Oncol. 2017 May 1;35(13):1384-1386. doi: 10.1200/JCO.2016.72.0045. Epub 2017 Mar 6. No abstract available.

PMID:
28447911
7.

Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study.

Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15. No abstract available.

8.

Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.

Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND.

Gynecol Oncol. 2017 Jun;145(3):549-554. doi: 10.1016/j.ygyno.2017.03.025. Epub 2017 Apr 6.

PMID:
28390820
9.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.

Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S.

J Natl Compr Canc Netw. 2017 Jan;15(1):9-20.

PMID:
28040716
10.

Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations-Reply.

Shu CA, Pike MC, Kauff ND.

JAMA Oncol. 2017 Mar 1;3(3):417-418. doi: 10.1001/jamaoncol.2016.3900. No abstract available.

PMID:
27832251
11.

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM Jr, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND.

JAMA Oncol. 2016 Nov 1;2(11):1434-1440. doi: 10.1001/jamaoncol.2016.1820.

12.

Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.

Hussein YR, Ducie JA, Arnold AG, Kauff ND, Vargas-Alvarez HA, Sala E, Levine DA, Soslow RA.

Am J Surg Pathol. 2016 Mar;40(3):404-9. doi: 10.1097/PAS.0000000000000556.

13.

Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy.

Shaukat A, Church TR, Shanley R, Kauff ND, O'Brien MJ, Mills GM, Jordan PA, Allen JA, Kim A, Feld AD, Zauber AG, Winawer SJ.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):913-20. doi: 10.1158/1055-9965.EPI-14-1321. Epub 2015 Mar 23.

14.

The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.

Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR.

Ann Oncol. 2014 Dec;25(12):2372-8. doi: 10.1093/annonc/mdu461. Epub 2014 Oct 3.

15.

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.

J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.

16.

Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.

Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber DA, Lipkin SM, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K.

J Clin Oncol. 2016 Mar 10;34(8):e61-7. doi: 10.1200/JCO.2013.50.0272. Epub 2014 Jun 30. No abstract available.

PMID:
24982446
17.

Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.

Arnold AG, Otegbeye E, Fleischut MH, Glogowski EA, Siegel B, Boyar SR, Salo-Mullen E, Amoroso K, Sheehan M, Berliner JL, Stadler ZK, Kauff ND, Offit K, Robson ME, Zhang L.

Breast Cancer Res Treat. 2014 Jun;145(3):625-34. doi: 10.1007/s10549-014-2987-6. Epub 2014 May 14.

PMID:
24825132
18.

Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.

Reyes MC, Arnold AG, Kauff ND, Levine DA, Soslow RA.

Mod Pathol. 2014 Oct;27(10):1405-11. doi: 10.1038/modpathol.2013.237. Epub 2014 Feb 28.

19.

American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, Kohlmann W, Lindor NM, Mulvey TM, Robinson L, Rubinstein WS, Stoffel EM, Snyder C, Syngal S, Merrill JK, Wollins DS, Hughes KS; American Society of Clinical Oncology.

J Clin Oncol. 2014 Mar 10;32(8):833-40. doi: 10.1200/JCO.2013.50.9257. Epub 2014 Feb 3. No abstract available.

20.

Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).

Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ.

Int J Gynecol Cancer. 2013 Nov;23(9):1603-11. doi: 10.1097/IGC.0b013e3182a80ac8.

21.

Screening for familial ovarian cancer: a ray of hope and a light to steer by.

Long KC, Kauff ND.

J Clin Oncol. 2013 Jan 1;31(1):8-10. doi: 10.1200/JCO.2012.45.4678. Epub 2012 Dec 3. No abstract available.

PMID:
23213103
22.

Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.

Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA.

Gynecol Oncol. 2012 Aug;126(2):224-8. doi: 10.1016/j.ygyno.2012.05.001. Epub 2012 May 8.

23.

Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.

Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA.

Mod Pathol. 2012 Apr;25(4):625-36. doi: 10.1038/modpathol.2011.183. Epub 2011 Dec 23.

24.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.

25.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

26.

Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.

Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D.

Gynecol Oncol. 2011 Nov;123(2):196-9. doi: 10.1016/j.ygyno.2011.07.019. Epub 2011 Aug 19.

27.

Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.

Shih KK, Garg K, Levine DA, Kauff ND, Abu-Rustum NR, Soslow RA, Barakat RR.

Gynecol Oncol. 2011 Oct;123(1):88-94. doi: 10.1016/j.ygyno.2011.06.005. Epub 2011 Jul 13.

PMID:
21742371
28.

Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.

Long KC, Kauff ND.

Curr Opin Oncol. 2011 Sep;23(5):526-30. doi: 10.1097/CCO.0b013e3283499da9. Review.

PMID:
21734577
29.

Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes.

Zhang L, Fleischut MH, Kohut K, Spencer S, Wong K, Stadler ZK, Kauff ND, Offit K, Robson ME.

Clin Genet. 2011 Jul;80(1):97-8. doi: 10.1111/j.1399-0004.2011.01691.x. No abstract available.

PMID:
21649643
30.

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.

Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME.

Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19.

31.

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.

Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D; BCFR Investigators, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D; EMBRACE Investigators, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O; GEMO Study Collaborators, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M; HEBON Investigators, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G; kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A; SWE-BRCA Investigators, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA; Ovarian Cancer Association Consortium.

Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8.

32.

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

Gallagher DJ, Konner JA, Bell-McGuinn KM, Bhatia J, Sabbatini P, Aghajanian CA, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Ann Oncol. 2011 May;22(5):1127-32. doi: 10.1093/annonc/mdq577. Epub 2010 Nov 17.

33.

Genome-wide association studies of cancer predisposition.

Stadler ZK, Vijai J, Thom P, Kirchhoff T, Hansen NA, Kauff ND, Robson M, Offit K.

Hematol Oncol Clin North Am. 2010 Oct;24(5):973-96. doi: 10.1016/j.hoc.2010.06.009. Review.

PMID:
20816582
34.

SGO White Paper on ovarian cancer: etiology, screening and surveillance.

Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ.

Gynecol Oncol. 2010 Oct;119(1):7-17. doi: 10.1016/j.ygyno.2010.06.003. Epub 2010 Aug 7. Review.

PMID:
20692025
35.

Genome-wide association studies of cancer.

Stadler ZK, Thom P, Robson ME, Weitzel JN, Kauff ND, Hurley KE, Devlin V, Gold B, Klein RJ, Offit K.

J Clin Oncol. 2010 Sep 20;28(27):4255-67. doi: 10.1200/JCO.2009.25.7816. Epub 2010 Jun 28.

36.

Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.

Stadler ZK, Saloustros E, Hansen NA, Schluger AE, Kauff ND, Offit K, Robson ME.

Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11.

PMID:
20221693
37.

Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.

Stadler ZK, Kauff ND.

J Clin Oncol. 2010 Jan 10;28(2):189-91. doi: 10.1200/JCO.2009.25.6875. Epub 2009 Dec 7. No abstract available.

PMID:
19996025
38.

A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer.

Zivanovic O, Carter J, Kauff ND, Barakat RR.

Gynecol Oncol. 2009 Dec;115(3):504-9. doi: 10.1016/j.ygyno.2009.08.011. Epub 2009 Sep 15. Review.

PMID:
19758691
39.

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

Vicus D, Rosen B, Lubinski J, Domchek S, Kauff ND, Lynch HT, Isaacs C, Tung N, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2009 Oct;115(1):135-137. doi: 10.1016/j.ygyno.2009.06.012. Epub 2009 Jul 3.

40.

ATR mutations in endometrial cancer: a window into the role of mismatch repair defects.

Kauff ND.

J Clin Oncol. 2009 Jul 1;27(19):3077-8. doi: 10.1200/JCO.2009.22.2125. Epub 2009 May 26. Review. No abstract available.

PMID:
19470916
41.

Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.

Garg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA.

Am J Surg Pathol. 2009 Jun;33(6):925-33. doi: 10.1097/PAS.0b013e318197a046.

PMID:
19238076
42.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

43.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.

J Clin Oncol. 2008 Mar 10;26(8):1331-7. doi: 10.1200/JCO.2007.13.9626. Epub 2008 Feb 11.

44.

Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?

Kauff ND.

J Clin Oncol. 2008 Jan 1;26(1):9-10. doi: 10.1200/JCO.2007.14.0244. No abstract available.

PMID:
18165631
45.

Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.

Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ; Society of Gynecologic Oncologists Education Committee.

Gynecol Oncol. 2007 Nov;107(2):159-62.

PMID:
17950381
46.

How should women with early-onset endometrial cancer be evaluated for lynch syndrome?

Kauff ND.

J Clin Oncol. 2007 Nov 20;25(33):5143-6. Epub 2007 Oct 9. No abstract available.

PMID:
17925541
47.

Screening and prevention of hereditary gynecologic cancers.

Kehoe SM, Kauff ND.

Semin Oncol. 2007 Oct;34(5):406-10. Review.

PMID:
17920895
48.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
49.

Modeling genetic risk of breast cancer.

Kauff ND, Offit K.

JAMA. 2007 Jun 20;297(23):2637-9. No abstract available.

PMID:
17579233
50.

Does a BRCA mutation plus tamoxifen equal hysterectomy?

Lu KH, Kauff ND.

Gynecol Oncol. 2007 Jan;104(1):3-4. No abstract available.

PMID:
17222708

Supplemental Content

Loading ...
Support Center